Skip to content
DataLookout
Menu

NCT07808515

A Study Comparing Cemiplimab-based Treatments for Adult Participants With Locally Advanced Basal Cell Skin Cancer (laBCC)

StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below.

  1. Minor Start date pushed from Oct 15, 2026 to Nov 13, 2026
  2. Study First Submitted
  • Minor: routine updates

Endpoints

Primary

Objective Response Rate (ORR) by blinded independent central review (BICR) per Composite Response Criteria
Timeframe: Up to approximately 3 years

Secondary (11)

Duration of Response (DOR) by BICR per Composite Response Criteria
Time to Response (TTR) by BICR per Composite Response Criteria
Best Overall Response (BOR) of Complete Response (CR) by BICR per composite Response Criteria
Progression-Free Survival (PFS) by BICR per Composite Response Criteria
Objective Response by investigator review per Composite Response Criteria
Show 6 moreShow less
DOR by investigator review per Composite Response Criteria
TTR by investigator review per Composite Response Criteria
Complete Response (CR) by investigator review per Composite Response Criteria
PFS by investigator review per Composite Response Criteria
Occurrence of Treatment-Emergent Adverse Events (TEAEs)
Severity of TEAEs

Arms and interventions

Arm AExperimental
Arm BExperimental
Arm CExperimental
Subsequent Therapy ArmExperimental

Drugs: Cemiplimab, Vidutolimod, Fianlimab